GlassScriptPhysician profile
Abdul L Amir
NPI 1255315081
$3,483.37
in general payments reported to CMS, 2019-2025
26 companies · $925 in 2025
The $925 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.29 · 2020: $1,757 · 2021: $545 · 2022: $221 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.79 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,622.11 | 2020-2025 | Inspire |
| Tactile Systems Technology INC | $388.15 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $273.35 | 2022-2025 | Tezspire, Fasenra, Breztri |
| Jazz Pharmaceuticals INC. | $223.32 | 2025 | |
| Boston Scientific Corporation | $98.82 | 2021 | |
| Medtronic, INC. | $81.04 | 2022 | |
| Cardiva Medical, INC. | $80.18 | 2020 | |
| United Therapeutics Corporation | $73.71 | 2025 | Tyvaso |
| Genzyme Corporation | $70.67 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $61.45 | 2025 | Dupixent |
| Glaxosmithkline, LLC. | $57.83 | 2025 | Nucala |
| Amgen INC. | $50.52 | 2025 | Tezspire |
| Angiodynamics, INC. | $44.06 | 2021 | |
| Harmony Biosciences LLC | $43.85 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.04 | 2025 | Glassia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $35.92 | 2021 | |
| Resmed Corp | $35.29 | 2019 | |
| Pulmonx Corporation | $33.15 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Edwards Lifesciences Corporation | $31.20 | 2020 | |
| Baxter Healthcare | $26.55 | 2025 | Hillrom - Monarch Airway Clearance System |
| Genentech USA, INC. | $24.09 | 2025 | Xolair |
| Veryan Medical Incorporated | $22.58 | 2021 | |
| Verona Pharma, INC. | $18.06 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $17.87 | 2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $17.54 | 2025 | |
| Cordis US Corp. | $15.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Amir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.